14 results on '"Kruchko, Carol"'
Search Results
2. Childhood, adolescent, and adult primary brain and central nervous system tumor statistics for practicing healthcare providers in neuro-oncology, CBTRUS 2015–2019.
- Author
-
Price, Mackenzie, Ryan, Katherine, Shoaf, Madison L, Neff, Corey, Iorgulescu, J Bryan, Landi, Daniel B, Cioffi, Gino, Waite, Kristin A, Kruchko, Carol, Barnholtz-Sloan, Jill S, and Ostrom, Quinn T
- Subjects
CENTRAL nervous system tumors ,MEDICAL personnel ,NURSE practitioners ,BRAIN tumors ,ONCOLOGY nursing ,SURVIVAL rate ,CENTRAL nervous system - Abstract
Background The Central Brain Tumor Registry of the United States (CBTRUS), in collaboration with the Centers for Disease Control and Prevention (CDC) and National Cancer Institute (NCI), is the largest aggregation of histopathology-specific population-based data for primary brain and other central nervous system (CNS) in the US. CBTRUS publishes an annual statistical report which provides critical reference data for the broad neuro-oncology community. Here, we summarize the key findings from the 2022 CBTRUS annual statistical report for healthcare providers. Methods Incidence data were obtained from the CDC's National Program of Cancer Registries (NPCR) and NCI's Surveillance, Epidemiology, and End Results Program for 52 central cancer registries (CCRs). Survival data were obtained from 42 NPCR CCRs. All rates are per 100 000 and age-adjusted using the 2000 US standard population. Overall median survival was estimated using Kaplan–Meier models. Survival data for selected molecularly defined histopathologies are from the National Cancer Database. Mortality data are from the National Vital Statistics System. Results The average annual age-adjusted incidence rate of all primary brain and other CNS tumors was 24.25/100 000. Incidence was higher in females and non-Hispanics. The most commonly occurring malignant and predominately non-malignant tumors was glioblastoma (14% of all primary brain tumors) and meningioma (39% of all primary brain tumors), respectively. Mortality rates and overall median survival varied by age, sex, and histopathology. Conclusions This summary describes the most up-to-date population-based incidence, mortality, and survival, of primary brain and other CNS tumors in the US and aims to serve as a concise resource for neuro-oncology providers. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
3. Complete prevalence of primary malignant and nonmalignant brain tumors in comparison to other cancers in the United States.
- Author
-
Neff, Corey, Price, Mackenzie, Cioffi, Gino, Kruchko, Carol, Waite, Kristin A., Barnholtz‐Sloan, Jill S., and Ostrom, Quinn T.
- Subjects
BRAIN tumors ,CENTRAL nervous system tumors ,AGE groups - Abstract
Background: Primary brain tumors (BTs) are rare, but cause morbidity and mortality disproportionately to their incidence. Prevalence estimates population‐level cancer burdens at a specified time. This study estimates the prevalence of malignant and non‐malignant BTs in comparison to other cancers. Methods: Incidence data were obtained from the Central Brain Tumor Registry of the United States (2000–2019, varying), a combined data set including the Center for Disease Control and Prevention's National Program of Cancer Registries and National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) Program. Incidence of non‐BT cancers were obtained from the United States Cancer Statistics (2001–2019). Incidence and survival estimates for all cancers were obtained from SEER (1975–2018). Complete prevalence as of December 31, 2019, was estimated using prevEst. Estimates were generated overall for non‐BT cancers, by BT histopathology, age groups at prevalence (0–14, 15–39, 40–64, 65+ years), and sex. Results: We estimated 1,323,121 individuals with a diagnosis of BTs at the date of prevalence. The majority of BT cases had non‐malignant tumors (85.3%). Among all cancers, BTs were the most prevalent cancer type among those ages 15 to 39 years, second among those ages 0 to 14 years, and in the top five among those ages 40 to 64 years. The plurality of prevalent cases (43.5%) occurred among those ages 65+ years. Overall, females had a higher prevalence of BTs than males, with an overall female:male prevalence ratio of 1.68. Conclusions: BTs contribute significantly to the cancer burden in the United States, particularly among those younger than age 65 years. Understanding complete prevalence is crucial for monitoring cancer burden to inform clinical research and public policy. We include a comparison of prevalence estimates for all primary brain tumors to other common cancers by age group in the United States. We also provide a description of the complete prevalence of primary malignant and nonmalignant brain and other central nervous system tumors in the United States for 2019, an update to a previous study. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
4. Completeness and concordancy of WHO grade assignment for brain and central nervous system tumors in the United States, 2004–2011
- Author
-
Lym, Ryan L., Ostrom, Quinn T., Kruchko, Carol, Couce, Marta, Brat, Daniel J., Louis, David N., and Barnholtz-Sloan, Jill S.
- Published
- 2015
- Full Text
- View/download PDF
5. Aligning the Central Brain Tumor Registry of the United States (CBTRUS) histology groupings with current definitions.
- Author
-
Waite, Kristin A, Cioffi, Gino, Kruchko, Carol, Patil, Nirav, Brat, Daniel J, Bruner, Janet M, McLendon, Roger E, Tihan, Tarik, Ostrom, Quinn T, and Barnholtz-Sloan, Jill S
- Subjects
BRAIN tumors ,HISTOLOGY ,CENTRAL nervous system tumors ,NOSOLOGY ,GENETIC markers ,DEFINITIONS - Abstract
Background The Central Brain Tumor Registry of the United States (CBTRUS) uses a histology grouping model based on the World Health Organization (WHO) classifications to group records for clinically relevant statistical reporting. Newly identified genetic markers more accurately stratify patients than histology alone and were incorporated into the 2016 update to the WHO Classification. Methods CBTRUS and consulting neuropathologists reviewed and aligned histology groupings with the 2016 WHO update. "Obsolete" (terms not currently in use) histology nomenclature along with their International Classification of Disease, Oncology 3rd edition (ICD-O-3) codes were identified, some histologies were reclassified to 2016 WHO, and new codes found in 2016 WHO were incorporated. An evaluation of the frequency of histology codes affected in the realignment process, and incidence and survival pre- and post-realignment was conducted. Results After review, 67 codes were noted as obsolete, 51 codes were reclassified, and 12 new codes were incorporated. Histology groups most affected were mesenchymal tumors and neuronal/mixed neuronal-glial tumors. Reorganization resulted in 2588 (0.65%) cases with grouping reassignment or reporting change, indicating that the 2016 WHO Classification revision has impacted the collection and reporting of primary brain and other CNS tumors. Conclusion This work demonstrates the need to be responsive to changes in classification and coding in order to ensure the most up-to-date and accurate statistics for brain and CNS tumors. This will require collaboration from all stakeholders within the brain tumor community, so to have the ability to reconcile clinical practices and surveillance requirements. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
6. Primary brain and other central nervous system tumors in the United States (2014-2018): A summary of the CBTRUS statistical report for clinicians.
- Author
-
Low, Justin T, Ostrom, Quinn T, Cioffi, Gino, Neff, Corey, Waite, Kristin A, Kruchko, Carol, and Barnholtz-Sloan, Jill S
- Subjects
CENTRAL nervous system tumors ,MEDICAL personnel ,DEATH rate - Abstract
Background The Central Brain Tumor Registry of the United States (CBTRUS) contains information on all primary brain and other central nervous system (CNS) tumors diagnosed in the United States (US). Here we summarize the 2021 CBTRUS annual statistical report for clinicians. Methods Incidence survival data are obtained from the Centers for Disease Control's National Program of Cancer Registries (NPCR) and National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) program. Survival data are obtained from NPCR. Mortality data are obtained from the National Vital Statistics System. Incidence and mortality rates are age-adjusted using the 2000 US population and presented per 100,000 population. Results An annual average of 86,355 cases of primary malignant and nonmalignant CNS tumors were diagnosed over the period 2014–2018, corresponding to an average annual age-adjusted incidence rate of 24.25. The most commonly occurring malignant tumor was glioblastoma (14.3%), and the most common predominately nonmalignant tumor was meningioma (39%). Over the 2014–2018 period, there were 16,606 annual average deaths due to malignant primary CNS tumors, corresponding to an average annual age-adjusted mortality rate of 4.43. In this report we detail key incidence, survival, and mortality statistics for major primary CNS tumor histologies, highlighting relevant differences by age, sex, and race. Conclusions This summary describes the most up to date population-based incidence of primary malignant and nonmalignant brain and other CNS tumors in the US, and mortality and survival for primary malignant tumors and aims to serve as a useful resource for clinicians. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
7. Brain and other central nervous system tumor statistics, 2021.
- Author
-
Miller, Kimberly D., Ostrom, Quinn T., Kruchko, Carol, Patil, Nirav, Tihan, Tarik, Cioffi, Gino, Fuchs, Hannah E., Waite, Kristin A., Jemal, Ahmedin, Siegel, Rebecca L., and Barnholtz‐Sloan, Jill S.
- Subjects
BRAIN tumors ,CENTRAL nervous system tumors ,AGE groups ,CENTRAL nervous system - Abstract
Brain and other central nervous system (CNS) tumors are among the most fatal cancers and account for substantial morbidity and mortality in the United States. Population‐based data from the Central Brain Tumor Registry of the United States (a combined data set of the National Program of Cancer Registries [NPCR] and Surveillance, Epidemiology, and End Results [SEER] registries), NPCR, National Vital Statistics System and SEER program were analyzed to assess the contemporary burden of malignant and nonmalignant brain and other CNS tumors (hereafter brain) by histology, anatomic site, age, sex, and race/ethnicity. Malignant brain tumor incidence rates declined by 0.8% annually from 2008 to 2017 for all ages combined but increased 0.5% to 0.7% per year among children and adolescents. Malignant brain tumor incidence is highest in males and non‐Hispanic White individuals, whereas the rates for nonmalignant tumors are highest in females and non‐Hispanic Black individuals. Five‐year relative survival for all malignant brain tumors combined increased between 1975 to 1977 and 2009 to 2015 from 23% to 36%, with larger gains among younger age groups. Less improvement among older age groups largely reflects a higher burden of glioblastoma, for which there have been few major advances in prevention, early detection, and treatment the past 4 decades. Specifically, 5‐year glioblastoma survival only increased from 4% to 7% during the same time period. In addition, important survival disparities by race/ethnicity remain for childhood tumors, with the largest Black‐White disparities for diffuse astrocytomas (75% vs 86% for patients diagnosed during 2009‐2015) and embryonal tumors (59% vs 67%). Increased resources for the collection and reporting of timely consistent data are critical for advancing research to elucidate the causes of sex, age, and racial/ethnic differences in brain tumor occurrence, especially for rarer subtypes and among understudied populations. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
8. Tumor Treating Fields for Glioblastoma Therapy During the COVID-19 Pandemic.
- Author
-
Gatson, Na Tosha N., Barnholtz-Sloan, Jill, Drappatz, Jan, Henriksson, Roger, Hottinger, Andreas F., Hinoul, Piet, Kruchko, Carol, Puduvalli, Vinay K., Tran, David D., Wong, Eric T., and Glas, Martin
- Subjects
COVID-19 pandemic ,ELECTRIC field therapy ,COVID-19 treatment ,CENTRAL nervous system tumors ,GLIOBLASTOMA multiforme ,OLDER patients - Abstract
Background: The COVID-19 pandemic has placed excessive strain on health care systems and is especially evident in treatment decision-making for cancer patients. Glioblastoma (GBM) patients are among the most vulnerable due to increased incidence in the elderly and the short survival time. A virtual meeting was convened on May 9, 2020 with a panel of neuro-oncology experts with experience using Tumor Treating Fields (TTFields). The objective was to assess the risk-to-benefit ratio and provide guidance for using TTFields in GBM during the COVID-19 pandemic. Panel Discussion: Topics discussed included support and delivery of TTFields during the COVID-19 pandemic, concomitant use of TTFields with chemotherapy, and any potential impact of TTFields on the immune system in an intrinsically immunosuppressed GBM population. Special consideration was given to TTFields' use in elderly patients and in combination with radiotherapy regimens. Finally, the panel discussed the need to better capture data on COVID-19–positive brain tumor patients to analyze longitudinal outcomes and changes in treatment decision-making during the pandemic. Expert Opinion: TTFields is a portable home-use device which can be managed via telemedicine and safely used in GBM patients during the COVID-19 pandemic. TTFields has no known immunosuppressive effects which is important during a crisis where other treatment methods might be limited, especially for elderly patients with multiple co-morbidities. It is too early to estimate the full impact of COVID-19 on the global healthcare system and on patient outcomes and the panel strongly recommended collaboration with existing cancer COVID-19 registries to follow CNS tumor patients. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
9. Relative survival after diagnosis with a primary brain or other central nervous system tumor in the National Program of Cancer Registries, 2004 to 2014.
- Author
-
Ostrom, Quinn T, Truitt, Gabrielle, Gittleman, Haley, Brat, Daniel J, Kruchko, Carol, Wilson, Reda, and Barnholtz-Sloan, Jill S
- Subjects
CENTRAL nervous system tumors ,BRAIN tumors ,PROGRESSION-free survival ,MEDICAL registries - Abstract
Background The majority of reported cancer survival statistics in the United States are generated using the National Cancer Institute's publicly available Surveillance, Epidemiology, and End Results (SEER) data, which prior to 2019 represented 28% of the US population (now 37%). In the case of rare cancers or special subpopulations, data sets based on a larger portion of the US population may contribute new insights into these low-incidence cancers. The purpose of this study is to characterize the histology-specific survival patterns for all primary malignant and nonmalignant primary brain tumors in the United States using the Centers for Disease Control and Prevention's National Program of Cancer Registries (NPCR). Methods Survival data were obtained from the NPCR (includes data from 39 state cancer registries, representing 81% of the US population). Relative survival rates (RS) with 95% CI were generated using SEER*Stat 8.3.5 from 2004 to 2014 by behavior, histology, sex, race/ethnicity, and age at diagnosis. Results Overall, there were 488 314 cases from 2004 to 2014. Overall 5-year RS was 69.8% (95% CI = 69.6%-69.9%). Five-year RS was 35.9% (95% CI = 35.6%-36.1%) for malignant and 90.2% (95% CI = 90.1%-90.4%) for nonmalignant tumors. Pilocytic astrocytoma had the longest 5-year RS (94.2%, 95% CI = 93.6%-94.6%) of all glioma subtypes, whereas glioblastoma had the shortest 5-year RS (6.1%, 95% CI = 6.0%-6.3%). Nonmalignant nerve sheath tumors had the longest 5-year RS (99.3%, 95% CI = 99.1%-99.4%). Younger age and female sex were associated with increased survival for many histologies. Conclusions Survival after diagnosis with primary brain tumor varies by behavior, histology, and age. Using such a database that includes more than 80% of the US population may represent national survival patterns. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
10. Cancer collection efforts in the United States provide clinically relevant data on all primary brain and other CNS tumors.
- Author
-
Kruchko, Carol, Gittleman, Haley, Ruhl, Jennifer, Hofferkamp, Jim, Ward, Elizabeth M, Ostrom, Quinn T, Sherman, Recinda L, Jones, Sandra F, Barnholtz-Sloan, Jill S, and Wilson, Reda J
- Subjects
- *
CENTRAL nervous system , *STANDARD-setting organizations , *BRAIN tumors , *TUMORS , *CANCER ,CENTRAL nervous system tumors - Abstract
Cancer surveillance is critical for monitoring the burden of cancer and the progress in cancer control. The accuracy of these data is important for decision makers and others who determine resource allocation for cancer prevention and research. In the United States, cancer registration is conducted according to uniform data standards, which are updated and maintained by the North American Association of Central Cancer Registries. Underlying cancer registration efforts is a firm commitment to ensure that data are accurate, complete, and reflective of current clinical practices. Cancer registries ultimately depend on medical records that are generated for individual patients by clinicians to record newly diagnosed cases. For the cancer registration of brain and other CNS tumors, the Central Brain Tumor Registry of the United States is the self-appointed guardian of these data. In 2017, the Central Brain Tumor Registry of the United States took the initiative to promote the inclusion of molecular markers found in the 2016 WHO Classification of Tumours of the Central Nervous System into information collected by cancer registries. The complexities of executing this latest objective are presented according to the cancer registry standard-setting organizations whose collection practices for CNS tumors are directly affected. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
11. Years of life lived with disease and years of potential life lost in children who die of cancer in the United States, 2009.
- Author
-
Blank, Peter M., Ostrom, Quinn T., Rouse, Chaturia, Wolinsky, Yingli, Kruchko, Carol, Salcido, Joanne, and Barnholtz‐Sloan, Jill S.
- Subjects
CANCER statistics ,DISEASE duration ,CHILDHOOD cancer ,CANCER in adolescence ,MORTALITY ,EPIDEMIOLOGY software ,CENTRAL nervous system tumors ,NEUROECTODERMAL tumors - Abstract
Incidence and survival rates are commonly reported statistics, but these may fail to capture the full impact of childhood cancers. We describe the years of potential life lost ( YPLL) and years of life lived with disease ( YLLD) in children and adolescents who died of cancer in the United States to estimate the impact of childhood cancer in the United States in 2009. We examined mortality data in 2009 among children and adolescents <20 years old in both the National Vital Statistics System ( NVSS) and the Surveillance, Epidemiology, and End Results ( SEER) datasets. YPLL and YLLD were calculated for all deaths due to cancer. Histology-specific YPLL and YLLD of central nervous system ( CNS) tumors, leukemia, and lymphoma were estimated using SEER. There were 2233 deaths and 153,390.4 YPLL due to neoplasm in 2009. CNS tumors were the largest cause of YPLL (31%) among deaths due to cancer and were the cause of 1.4% of YPLL due to all causes. For specific histologies, the greatest mean YPLL per death was due to atypical teratoid/rhabdoid tumor (78.0 years lost). The histology with the highest mean YLLD per death in children and adolescents who died of cancer was primitive neuroectodermal tumor (4.6 years lived). CNS tumors are the most common solid malignancy in individuals <20 years old and have the highest YPLL cost of all cancers. This offers the first histology-specific description of YPLL in children and adolescents and proposes a new measure of cancer impact, YLLD, in individuals who die of their disease. YPLL and YLLD complement traditional indicators of mortality and help place CNS tumors in the context of other childhood malignancies. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
12. Trends in central nervous system tumor incidence relative to other common cancers in adults, adolescents, and children in the United States, 2000 to 2010.
- Author
-
Gittleman, Haley R., Ostrom, Quinn T., Rouse, Chaturia D., Dowling, Jacqueline A., de Blank, Peter M., Kruchko, Carol A., Elder, J. Bradley, Rosenfeld, Steven S., Selman, Warren R., Sloan, Andrew E., and Barnholtz‐Sloan, Jill S.
- Subjects
CENTRAL nervous system tumors ,HODGKIN'S disease ,CANCER research ,LYMPHOBLASTIC leukemia in children ,CONFIDENCE intervals - Abstract
BACKGROUND Time trends in cancer incidence rates (IR) are important to measure the changing burden of cancer on a population over time. The overall IR of cancer in the United States is declining. Although central nervous system tumors (CNST) are rare, they contribute disproportionately to mortality and morbidity. In this analysis, the authors examined trends in the incidence of the most common cancers and CNST between 2000 and 2010. METHODS The current analysis used data from the United States Cancer Statistics publication and the Central Brain Tumor Registry of the United States. Age-adjusted IR per 100,000 population with 95% confidence intervals and the annual percent change (APC) with 95% confidence intervals were calculated for selected common cancers and CNST overall and by age, sex, race/ethnicity, selected histologies, and malignancy status. RESULTS In adults, there were significant decreases in colon (2000-2010: APC, −3.1), breast (2000-2010: APC, −0.8), lung (2000-2010: APC, −1.1), and prostate (2000-2010: APC, −2.4) cancer as well as malignant CNST (2008-2010: APC, −3.1), but a significant increase was noted in nonmalignant CNST (2004-2010: APC, 2.7). In adolescents, there were significant increases in malignant CNST (2000-2008: APC, 1.0) and nonmalignant CNST (2004-2010: APC, 3.9). In children, there were significant increases in acute lymphocytic leukemia (2000-2010: APC, 1.0), non-Hodgkin lymphoma (2000-2010: APC, 0.6), and malignant CNST (2000-2010: APC, 0.6). CONCLUSIONS Surveillance of IR trends is an important way to measure the changing public health and economic burden of cancer. In the current study, there were significant decreases noted in the incidence of adult cancer, whereas adolescent and childhood cancer IR were either stable or increasing. Cancer 2015;121:102-112. © 2014 The Authors. Cancer published by Wiley Periodicals, Inc. on behalf of American Cancer Society. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
13. Consensus Conference on Cancer Registration of Brain and Central Nervous System Tumors.
- Author
-
McCarthy, Bridget J. and Kruchko, Carol
- Subjects
BRAIN tumors ,CENTRAL nervous system tumors ,CONFERENCES & conventions ,MEDICAL laws ,CANCER -- Law & legislation - Abstract
The passage of Public Law 107-260, the Benign Brain Tumor Cancer Registries Amendment Act, in October 2002 has made the collection of all primary brain tumors a reality. However, at the first Consensus Conference on Brain Tumor Definition for Registration in 2002, and during the development of training materials for benign brain tumor collection, several issues were identified that were tabled for future discussion. These and other issues were addressed at the subsequent 2003 Consensus Conference on Cancer Registration of Brain and Central Nervous System Tumors, at which the Central Brain Tumor Registry of the United States facilitated a discussion among epidemiologists, neurosurgeons, and neuropathologists. Multidisciplinary consensus was reached on four points, for which the following recommendations were made: (1) amend the histology coding scheme for cysts and tumor-like lesions that currently have a code in the third edition of the International Classification of Disease for Oncology (ICDO), (2) collect data on all instances of specific cysts and tumor-like lesions that are located in brain and other CNS sites but currently lack ICDO codes, (3) establish a new ICDO topography site for skull base tumors for the brain and CNS, and (4) collect data on genetic syndromes in patients diagnosed with brain or CNS tumors. We view this conference as part of a continuing process. Because classification of primary intracranial and other CNS tumors is dynamic, and the registration and coding of these tumors will need to be periodically reviewed. [ABSTRACT FROM AUTHOR]
- Published
- 2005
- Full Text
- View/download PDF
14. Descriptive Epidemiology of Spinal Meningiomas in the United States.
- Author
-
Kshettry, Varun R., Hsieh, Jason K., Ostrom, Quinn T., Kruchko, Carol, Benzel, Edward C., and Barnholtz-Sloan, Jill S.
- Subjects
- *
EPIDEMIOLOGY , *MENINGIOMA , *SPINE diseases , *SPINAL tumors , *HEALTH planning ,CENTRAL nervous system tumors - Abstract
Study Design. Cross-sectional study of US cancer registry data. Objective. To present the current population-based descriptive epidemiology of spinal meningiomas in the United States. Summary of Background Data. Meningioma is the most common primary spinal tumor, yet there is a paucity of population-based data evaluating incidence according to age, sex, race, and ethnicity. Such data are necessary to assess the burden of spinal meningiomas on varying populations and to inform health care planning and future research. Methods. The Central Brain Tumor Registry of the United States, which contains the largest aggregation of population-based data on the incidence of primary central nervous system tumors in the United States, was used. Age-adjusted incidence rates of spinal meningiomas from 2004 to 2010 were calculated by age at diagnosis, sex, race, and ethnicity. Annual percent change was calculated using Joinpoint to characterize temporal trends. Results. From 2004 to 2010, there were 7148 newly diagnosed spinal meningiomas, resulting in an overall age-adjusted incidence of 0.33 per 100,000 population. There was a nonsignificant increase in incidence over time (annual percent change: 0.8%, 95% confidence interval: - 1.4 to 3.0). The highest incidence occurred in the 75- to 84-year old age group. Females had a much higher incidence than males (incidence rate ratio: 3.37; P < 0.0001). Asian Pacific Islanders and Caucasians had the highest incidence. Compared with Caucasians, African Americans and American Indian/Alaskan Native individuals had a significantly lower incidence (incidence rate ratio: 0.72, P < 0.0001; 0.52, P = 0.0003, respectively). Non-Hispanics had a significantly lower incidence than Hispanics (incidence rate ratio: 0.81, P < 0.0001). Conclusion. Approximately 1000 spinal meningiomas were diagnosed in the United States per year, and the incidence was relatively stable. Advanced age, female sex, Asian Pacific Islander and Caucasian race, and Hispanic ethnicity were all associated with an increased incidence of spinal meningioma. This study represents the most comprehensive evaluation of population-based descriptive epidemiology of spinal meningiomas in the United States to date. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.